home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  
 

registry of biomedical companies

 
  September 27, 2016
promoting the transfer of scientific know-how between industry and academia
 
 
Registry of biomedical companies:

[3] [4] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 648 active entries

Polymun Scientific Immunbiologische Forschung GmbH

Donaustr. 99
Klosterneuburg, 3400
Austria

Phone: +43 2243 25060 300
Fax: +43 2243 25060 399
E-Mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Description:

Core competences

- Development and manufacturing of biopharmaceutical under GMP-conditions for clinical studies as well as for the market with focus on mammalian cell technology but also microbial cell technology – as contractor and for own R&D projects.
- Development and manufacturing of liposomal formulations under GMP-conditions for clinical studies as well as for the market – as contractor and for own R&D projects.

Contract Services offered:

Contract Development and Manufacturing of Biopharmaceuticals
The core competence of Polymun is the development and GMP-compliant manufacture of biopharmaceuticals, using both mammalian and microbial cell technology. Polymun holds a pharmaceutical production license under paragraph 63 of the Austrian Pharmaceutical Law, thus fulfilling all EU regulations, and is inspected by FDA. Polymun offers all steps from the gene to clinical grade material for innovator and generic products. Polymun has gathered experience in designing purification processes for proteins of all kinds - antibodies, hormones and enzymes. A wide range of analytical methods is available that can be readily adapted to new requirements. GMP-compliance and industrial applicability are central to all operations. Contract manufacturing includes the preparation of IMPD and CMC documents. Based on our own experience we are able to support planning of phase I-III clinical trials. As small, independent and private company Polymun has no conflict of interests thus granting a high degree of flexibility and security for its clients including the possibility of technology transfer.
Capacity:
Mammalian cell culture:
- Stirred tank: 15 L, 240 L, 2x 2500 L
- Ultrasonic cell retention: up to 100 L continuous perfusion culture
Yeast/Bacteria:
- Stirred tank: 50 L, 750 L
Downstream purification:
- Process systems up to 600 L/h and 6 bar

Contract Development and Manufacturing of Liposomal Formulations
Liposomes protect, transport and release your drug at the right place and time. By this, a reduced dose achieves better efficacy and avoids side effects by a non-invasive application. Polymun offers the development of liposomal formulations for all kinds of active pharmaceutical ingredients and vaccine antigens. We manufacture GMP-material including all necessary documentation and assist in planning of clinical trials. License agreements for Polymun’s patented liposome production technology are offered for the respective substance on an exclusive basis. Contracts can be arranged step by step - proof of concept, in-depth analysis, GMP-material production, product license - or all in one. Industrial applicability is the focus throughout each project. Polymun’s technology enables the industrial realization of pharmaceutical and cosmetic products for liposomal drug formats. The production technology is suitable for a broad range of substances formulated by passive entrapment, active loading or membrane incorporation.
Main characteristics of our technology are:
- Scalability
- Sterility
- Homogeneous, uniform vesicles
- Entrapment of several product classes with high efficiency
- Batch to batch consistency
- Stability due to a mild procedure

Own R&D Projects:

Human Monoclonal Antibodies against HIV-1
Polymun has established three human monoclonal antibodies (C2F5, C2G12 & C4E10) produced in recombinant CHO cells for therapeutic or prophylactic treatment of HIV-1 patients. Clinical phase I trials have been completed successfully as well as two phase II trials, one at the university hospital in Zurich and the other in New York (Aaron Diamond Aids Research Center, Dr. Markowitz) under IND of the FDA. Another phase I clinical trial was performed within the EU-project EMPRO using the antibodies as a vaginally administered microbicides in a gel formulation. Collaborative partnerships in development and marketing are still possible.

LipoxysanTM
Polymun has incorporated human recombinant Cu/Zn-Superoxiddismutase (SOD) into liposomes. The concept of transdermally administered SOD as a radical scavenger for the treatment of inflammations has manifold possibilities; quasi as an alternative to cortisone treatment, but free of any adverse effects.
Polymun finished a phase III clinical trial for the transdermal application of LipoxysanTM in human volunteers suffering from IPP (Induratio Penis Plastica) successfully. Polymun is planning trials for other indications, such as atopic lung- and bronchial inflammation as well as heat- and UV-burns. In May 2015, Polymun has signed a license agreement with ScarletRed for development and marketing of SOD.

Human Recombinant Trypsin
Polymun has a proprietary recombinant human Trypsin that is autocatalytically activated to the active enzyme. This product is intended to replace trypsin of animal origin. It has defined activity (e.g. free of chymotrypsin activity without inhibitor treatment) and is free of tissue born contaminants.
Polymun is currently establishing GMP-conform manufacturing processes and in contact with potential international marketing partners.

Influenza Vaccine Technology
Polymun has established a nasal spray vaccine employing live attenuated influenza virus strains produced on Vero cells. This candidate vaccine has passed a clinical proof of concept study. A patent was granted for the vaccine strains.
Polymun developed recombinant attenuated influenza as vaccine carrier to present foreign antigens. Polymun established functional techniques and selection systems using the interferon deficient Vero cell line to introduce large foreign gene-sequences into the NS1 gene of influenza. Successful constructs have been tested for HIV and tuberculosis (TB) in vitro and in vivo. lymun also created similar constructs for (TB) using ESAT-6 as antigen. Polymun is looking for an investor who wants to continue with this technology.



Selected Categories:
Product Company   Service Company
Biopharma
- General
- Research
Biotech
- General
Pharmaceutical
- General
Contract
- Production
- Research
- Services

Last update of this entry: May 14, 2015

Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 1995-2016 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.